



On the Pricing of Longevity-Linked Securities

**Daniel Bauer
Matthias Börger
Jochen Ruß**

September 2008

Helmholtzstraße 22
D-89081 Ulm
phone +49 (0) 731/50-31230
fax +49 (0) 731/50-31239
email ifa@ifa-ulm.de



Institut für Finanz- und
Aktuarwissenschaften



Agenda

- **Introduction**
- **Different Approaches for Pricing Longevity-Linked Securities**
- **Theoretical Comparison of the Approaches**
- **Empirical Comparison of the Approaches**
- **An Option-Type Longevity Derivative**
- **Conclusion**

Introduction

- **Longevity risk = The risk that future mortality improvement exceeds today's assumptions**
 - **Important risk factor** for annuity providers and pension funds
 - **Importance of this risk will increase** in the future
 - reduction of benefits from public pension systems
 - tax incentives for annuitization
 - **Securitization is seen as a solution** for managing this risk:
 - In the literature: Survivor bonds; survivor swaps, longevity bonds,...
 - In practice: First attempt to issue a longevity linked security failed.
 - However: There appears to be a consensus that suitable instruments will be available in the near future
 - Interesting question: **How to price** such instruments
 - What are suitable (actuarial or economic) methods?
 - How can such methodologies be applied (calibration, etc.)?

Different Approaches for Pricing Longevity-Linked Securities

- Price of a longevity derivative depends on the estimate of uncertain future mortality trends and the degree of uncertainty of this estimate → **Mortality risk premium (MRP)**
- Problem: There are no liquidly traded securities → MRP can not be observed in the market
- Consequence: Different pricing methods have been proposed
- **CAPM/CCAPM based approach (Friedberg and Webb 2007)**
 - MRP suggested by the models is very low (MRP-puzzle similar to equity premium puzzle)
 - → Probably limited applicability of this approach
- **Instantaneous Sharpe Ratio (ISR) based approach (Milevsky et al. 2005; Bayraktar et al. 2008)**
 - Investor in longevity risk requires compensation according to some ISR (λ)
 - Return in excess of risk free return = λ * standard deviation (after diversifiable risk is “hedged”)
 - For large portfolio size this coincides with a change of probability measure (P→Q) with a constant market price of risk
- **Wang Transform based approach (Lin and Cox 2005, 2006)**
 - Adjust the cdf of the future lifetime by a Wang transform to account for risk:
 ${}_t q_x^Q = \Phi(\Phi^{-1}({}_t q_x^P) - \theta)$ or ${}_t q_x^Q = \Psi(\Phi^{-1}({}_t q_x^P) - \theta)$

Theoretical Comparison of the Approaches

Our methodology

■ Establish the different approaches in a common framework

- “Forward Mortality Framework” (Details see Bauer et al. (2007))
- $\hat{\mu}_t(T, x_0) = -\frac{\partial}{\partial T} \log \{E_P [{}_T p_{x_0} | \mathfrak{F}_t]\}$
- Dynamics $d\hat{\mu}_t(T, x_0) = \hat{\alpha}(t, T, x_0)dt + \hat{\sigma}(t, T, x_0)dW_t$, $\hat{\mu}_0(T, x_0) > 0$
- Here: $\hat{\sigma}$ deterministic, W finite dimensional Brownian motion

■ Derive Pricing Formulas for “simple” (T, x_0) -Longevity bonds based on different approaches (simple longevity bonds pays ${}_T p_x$ at time T , “longevity zero”)



1. Wang Transform Approach: $\Pi_0(T, x_0) = B(0, T) \cdot (1 - \Phi(\Phi^{-1}(1 - E_P [{}_T p_{x_0}]) - \theta))$
2. Sharpe Ratio Approach: $\Pi_0(T, x_0) = B(0, T) \cdot \exp \left\{ \lambda \int_0^T \int_0^s \|\hat{\sigma}(u, s, x_0)\| du ds \right\} \cdot E_P [{}_T p_{x_0}]$
3. “Generic” model: $\Pi_0(T, x_0) = B(0, T) \cdot \exp \left\{ - \int_0^T \int_0^s \hat{\sigma}(u, s, x_0) \cdot \lambda(u) du ds \right\} \cdot E_P [{}_T p_{x_0}]$
($\lambda(\cdot)$ is a negative MPR process)

Theoretical Comparison of the Approaches (ctd.)

- **What is a good basis for determining θ and λ ?**
 - Loeys et al.: (Sharpe ratio from) **stock markets**
 - **But:** different characteristics
 - Adequacy questionable!
 - Lin & Cox: **Annuity Prices**
 - Strong empirical evidence that there is a mortality risk premium embedded in annuity prices
- **If there is one, which is the better of the two approaches?**
 - Wang transform not coherent with “generic” pricing formula if more than one age cohort is considered.
 - In line with Pelsser, 2008: Inconsistency with arbitrage-free prices
 - Hence, the Sharpe ratio approach is the more general and better approach

Empirical Comparison of the Approaches

- We use the “Volatility of Mortality” model from Bauer et al (2007) and recalibrate to UK data
- We derive Sharpe Ratios and Wang Transform parameters from monthly UK annuity quotes (November 2000 to July 2006)



- We find significant correlation between the market price of mortality risk and stock markets / interest rates
→ Assumption of independence between **risk-adjusted** mortality evolution and financial markets seems to be inadequate

Empirical Comparison of the Approaches (ctd.)

- **We then apply different pricing methodologies to the EIB/BNP-Bond**
 - Sharpe Ratio calibrated to UK annuity quotes
 - Sharpe Ratio from stock markets
 - 1 factor Wang Transform calibrated to UK annuity quotes
 - 1 factor Wang Transform calibrated to US annuity quotes (Calibration from Lin and Cox 2005)
 - 2 factor Wang Transform calibrated to UK annuity quotes
 - 2 factor Wang Transform calibrated to US annuity quotes (Calibration from Lin and Cox 2006)
- **Design of the EIB/BNP-Bond**
 - Notional = GBP 50m; Pays annual coupons for 25 years
 - Coupons depend on mortality experience of English and Welsh males aged 65 in 2003
- **The EIB/BNP-Bond is therefore essentially equivalent to a portfolio of (T,65)-Longevity Bonds for $T=1,2,\dots,25$**
- **The EIB/BNP-Bond was offered at GBP 540m**
 - discounting best estimate coupon payments at LIBOR-35bp
- **EIB's yield curve is about LIBOR-15bp → 20bp can be interpreted as “fee for the longevity hedge”**

Empirical Comparison of the Approaches (ctd.)

- **Lin and Cox (2006): Risk premium is very high → Bond is unattractive**
 - Conclusion is based on a Wang Transform approach
- **Cairns et al. (2006): Price seems reasonable**
 - Conclusion is based on an approach similar to an Instantaneous Sharpe Ratio approach
- **We “repriced” the bond using the 6 methods above and two hypothetical bonds of the same design but being offered in 2001 and 2006, respectively**

| | 11/2001 | 11/2004 | 7/2006 |
|--------|-----------|---------|-----------|
| Actual | <i>na</i> | 540 | <i>na</i> |
| SRUK | 487.56 | 584.40 | 605.50 |
| SRLOE | 540.42 | 580.60 | 597.95 |
| 1WTUK | 482.19 | 601.02 | 618.74 |
| 1WTLC | 530.87 | 563.42 | 576.32 |
| 2WTUK | 480.03 | 595.77 | 612.33 |
| 2WTLC | 516.91 | 548.27 | 560.72 |

- **Significant differences between issue dates**
 - Due to changes in interest rates, mortality projections and Sharpe Ratio / Wang Transform parameter calibrations
- **Significant differences between the 6 models**
- **All models result in a value that exceeds the price → The Bond was a “good deal”**

Empirical Comparison of the Approaches (ctd.)

- **If all 6 pricing models state that the EIB/BNP-Bond was a good deal, 2 questions arise:**
 - Why did Lin & Cox regard the Bond as too expensive?
 - They used a different yield curve and survival rates based on realized mortality rates in 2003 as opposed to projections
 - Why was it not successfully placed?
 - Based on population as opposed to inureds (basis risk)
 - Fixed maturity of the bond → tail risk is not hedged
 - Capital intensive hedge

- **→ We conclude that the financial engineering and not the pricing was the reason for the failure of the EIB/BNP-Bond.**
 - Therefore, in the final section, we analyzed a call-option-type longevity derivative

An Option-Type Longevity Derivative


- **Payoff:** $C_T = \left({}_T p_{x_0} - K(T) \right)^+$ with strike $K(T) = (1+a)E_P \left[{}_T p_{x_0} \right]$, $a > 0$
- **By suitable adjustment of the strike (choice of the parameter a), the insurer can decide, which portion of the risk to keep**
 - Example: No hedge against small deviation of actual/expected longevity. Hedge only against a deviation of more than, say, 10%
- **Such derivatives can be priced within our framework with a Black-type formula (Bauer 2007)**

| a | | $T = 5$ | $T = 10$ | $T = 15$ | $T = 20$ | $T = 25$ | $T = 30$ |
|-----|-------|---------|----------|----------|----------|----------|----------|
| 2% | SRUK | 0.00486 | 0.03678 | 0.07483 | 0.09079 | 0.07223 | 0.03827 |
| | SRLOE | 0.00443 | 0.03357 | 0.06752 | 0.08071 | 0.06316 | 0.03277 |
| | 1WTUK | 0.01532 | 0.04780 | 0.07357 | 0.08069 | 0.06447 | 0.03430 |
| | 1WTLC | 0.00634 | 0.02669 | 0.04235 | 0.04386 | 0.03127 | 0.01442 |
| | 2WTUK | 0.00580 | 0.03838 | 0.07034 | 0.08423 | 0.07168 | 0.04237 |
| | 2WTLC | 0.00075 | 0.01694 | 0.03545 | 0.04008 | 0.03066 | 0.01771 |
| 5% | SRUK | 0.00049 | 0.02639 | 0.06665 | 0.08573 | 0.06977 | 0.03744 |
| | SRLOE | 0.00043 | 0.02372 | 0.05973 | 0.07589 | 0.06081 | 0.03197 |
| | 1WTUK | 0.00342 | 0.03582 | 0.06545 | 0.07587 | 0.06210 | 0.03348 |
| | 1WTLC | 0.00076 | 0.01816 | 0.03630 | 0.04030 | 0.02957 | 0.01386 |
| | 2WTUK | 0.00066 | 0.02772 | 0.06239 | 0.07933 | 0.06922 | 0.04151 |
| | 2WTLC | 0.00003 | 0.01075 | 0.03003 | 0.03671 | 0.02899 | 0.01708 |
| 10% | SRUK | 0.00025 | 0.01366 | 0.05422 | 0.07768 | 0.06578 | 0.03606 |
| | SRLOE | 0.00022 | 0.01195 | 0.04800 | 0.06826 | 0.05703 | 0.03066 |
| | 1WTUK | 0.00215 | 0.02013 | 0.05313 | 0.06824 | 0.05829 | 0.03216 |
| | 1WTLC | 0.00041 | 0.00855 | 0.02762 | 0.03488 | 0.02693 | 0.01296 |
| | 2WTUK | 0.00035 | 0.01454 | 0.05038 | 0.07154 | 0.06525 | 0.04010 |
| | 2WTLC | 0.00001 | 0.00445 | 0.02240 | 0.03159 | 0.02637 | 0.01608 |

- **As expected: ↗↘ in T**
- **As expected: ↘ in a**
- **Wang prices higher for short maturities and vice versa**
- **Sometimes large differences despite calibration to the same data**


An Option-Type Longevity Derivative

- The risk premium allocations differ considerably between the pricing approaches



An Option-Type Longevity Derivative

- The risk premium allocations differ considerably between the pricing approaches



- red: Sharpe ratio approach
- green: 1-factor Wang transform approach
- blue: 2-factor Wang transform approach

- **Sharpe ratio approach: risk premium proportional to aggregated risk**
- **Wang Transform: risk premium allocation independent of actual risk**
- **→ Adequacy of the Wang Transform again questionable**

Conclusion

- **Overview and comparison of different pricing approaches**
- **Risk premium implied by the Wang Transform induces inconsistencies if securities on different ages are traded**
 - Even if just one security is traded, the “risk premium allocation” appears questionable
- **We conclude that currently a “market price of longevity risk” should be derived from annuity quotes**
 - Adopting Sharpe Ratios from equity markets appears to have weaknesses
- **We identify significant correlation between the market price of longevity risk and stock markets / interest rates**
 - Assuming independence between **risk-adjusted** mortality evolution and financial markets seems to be inadequate
- **The EIB/BNP-Bond appears to have been offered at a “good price”**
 - Reason for failure was financial engineering rather than pricing

■ **www.mortalityrisk.org**

- Exchange platform for latest papers and results on mortality/longevity risk and modeling
- Run by a Research Training Group at Ulm University
- You are encouraged to submit your papers!
- submission@mortalityrisk.org



References

- Bauer, D., 2007. Stochastic Mortality Modeling and Securitization of Mortality Risk. ifa-Verlag, Ulm (Germany).
- Bauer, D., B"orger, M., Ru"b, J., Zwiesler, H.-J., 2007. The Volatility of Mortality. To appear in: The Asia-Pacific Journal of Risk and Insurance.
- Bayraktar, E., Milevsky, M.A., Promislow, S.D., Young, V.R., 2008. Valuation of Mortality Risk via the Instantaneous Sharpe Ratio: Applications to Life Annuities. Working Paper, University of Michigan and York University.
- Cairns, A.J., Blake, D., Dawson, P., Dowd, K., 2006. Pricing the Risk on Longevity Bonds. Life and Pensions, October 2005: 41–44.
- Friedberg, L., Webb, A., 2007. Life is Cheap: Using Mortality Bonds to Hedge Aggregate Mortality Risk. The B.E. Journal of Economic Analysis & Policy, 7.
- Lin, Y., Cox, S., 2005. Securitization of Mortality Risks in Life Annuities. The Journal of Risk and Insurance, 72: 227–252.
- Lin, Y., Cox, S., 2006. Securitization of Catastrophe Mortality Risks. To appear in: Insurance: Mathematics and Economics.
- Loeys, J., Panigirtzoglou, N., Ribeiro, R.M., 2007. Longevity: a market in the making. Working Paper, JPMorgan Global Market Strategies.
- Milevsky, M.A., Promislow, S.D., Young, V.R., 2005. Financial Valuation of Mortality Risk via the Instantaneous Sharpe Ratio. Working Paper, York University and University of Michigan.
- Pelsser, A. , 2008. On the Applicability of the Wang Transform for Pricing Financial Risks. To appear in: ASTIN Bulletin.